Prognostic factors for multiple myeloma.

G. Reibnegger,D. Fuchs,H. Wachter
IF: 20.3
Blood
Abstract:A recent editorial in Blood by Kyle' underscored the need for better prognostic factors for multiple myeloma. The conclusions regarding neopterin, alone and in combination with interleukin-6 (IL-6). deserve some comments: Neopterin is produced in strongly increased quantities by human rnonocyteshacrophages stimulated by interferon y 2 and is a sensitive indicator for the activation of the cellular immune system.' Besides being a valuable immune activation marker in, eg, infectious and autoimmune diseases and recipients of allografts, neopterin was shown to be an independent predictor of survival in various malignant diseases4 In a study on neopterin and IL-6 in patients with multiple myelomas we have found that there is a different information content associated with both analytes: both IL-6 and neopterin were significantly and positively correlated with tumor stage. The correlation was stronger for IL-6, in good accordance with its proven role as a major growth factor of plasma cells. When performing product-limit analyses of survival using, separately, IL-6 and neopterin as grouping factors, the effect of neopterin on patient survival expectation was more pronounced ( P = .oOOl, Mantel-Cox test) than that of IL-6 ( P = ,025). However, when other potential predictor variables were included into a multivariate model by Cox regression, the inclusion of tumor stage (P = ,0048, multivariate model) into the model prevented the inclusion of IL-6 ( P > . I O ) but not of neopterin (P = .0050). On the other hand, when combining IL-6 and neopterin in a bivariate model, both variables were included (IL-6, P = ,053; neopterin, P < .OOOl). We concluded from these data that IL-6 is a better indicator than neopterin of current tumor load and disease severity that is biologically reasonable because of the growth factor role of the cytokine. However, neopterin as a global measure of the overall status of the host cellular immune system is a better and, importantly, statistically independent predictor of long-term survival. Clearly, IL-6 and neopterin measure quite different aspects of the disease. We think that the addition of neopterin into the panel of candidate prognostic factors for multiple myeloma would be promising: it sheds light on aspects of the disease that are certainly of importance for survival but that are not well described by other predictor variables.
What problem does this paper attempt to address?